U.S. Healthcare Services Stock News

Corteva and bp recently launched Etlas, a 50:50 joint venture to develop crop-based feedstocks for sustainable aviation fuel and renewable diesel, targeting initial supply from 2027 and scaling to one million tonnes of feedstock annually by the mid-2030s. By turning intermediate crops like canola, mustard and sunflower into low-carbon fuel feedstocks grown on existing farmland, Etlas links Corteva’s seed innovation directly to emerging demand for cleaner transportation fuels while offering...

In recent days, Wells Fargo upgraded ConocoPhillips to Overweight, citing expectations for stronger dividend growth supported by reduced capital spending and future cash flow from the Willow project, while other developments highlighted the company’s gas discovery in Australia and continued use of its LNG technology in third‑party projects. An interesting angle for investors is how the long‑dated Willow development and growing LNG technology footprint could reshape ConocoPhillips’ cash...

If you are wondering whether Cardinal Health's current share price still offers value after a strong run, this breakdown is designed to help you weigh that up with clear, grounded numbers. The stock recently closed at US$213.56, with returns of 3.1% over 7 days, 6.8% over 30 days, 3.8% year to date, 73.4% over 1 year, 194.7% over 3 years and 341.4% over 5 years. These figures may have shifted how some investors think about its risk and reward profile. Recent coverage of Cardinal Health has...

Royal Gold (RGLD) has drawn fresh attention after reporting approximately 64,000 gold equivalent ounces of stream segment sales for Q4 2025, along with a $400 million reduction in borrowings following the Sandstorm transaction. See our latest analysis for Royal Gold. These updates on stream sales, debt reduction and reshaped royalty exposure appear to sit alongside strong price momentum, with a 30 day share price return of 17.68% and a 1 year total shareholder return of 87.62%. This suggests...

On 14 January 2026, BWX Technologies presented at the CJS Securities 26th Annual “New Ideas for the New Year” Investor Conference, highlighting its position in nuclear and medical technologies. A key focus was BWXT Medical’s progress toward FDA approval of a Technetium-99m generator using commercially produced molybdenum, which could strengthen domestic supply security for high-volume diagnostic imaging procedures. We’ll now examine how BWXT Medical’s Technetium-99m generator progress and...

If you are wondering whether Luckin Coffee at around US$34.15 is still a worthwhile addition to your watchlist, the key question is how its current price lines up with its underlying value. The stock has had mixed recent returns, with a 1.3% gain over the last 7 days, a 1% decline over the last 30 days, a 3.6% decline year to date, and a 34.5% return over the past year. The 3-year return sits at 49.1%, and the 5-year return is very large. Recent news around Luckin Coffee has focused on its...

Framing EOG Resources after recent performance EOG Resources (EOG) has drawn fresh attention after a recent rebound, with the stock up 2.5% over the past day and 8% over the past week. This movement invites a closer look at its fundamentals. See our latest analysis for EOG Resources. While the recent 7 day share price return of 7.99% and 1 month share price return of 4.54% suggest short term momentum is building, the 1 year total shareholder return of 16.41% decline and 3 year total...

Why EZCORP’s latest earnings and rating shift matter for investors EZCORP (EZPW) recently reported quarterly earnings that exceeded analyst expectations, coinciding with a move from a “strong-buy” to “buy” rating at one research outlet while other brokerages kept positive views in place. This combination of strong results and a modest rating change gives you a fresh data point to consider when assessing how the pawn-focused lender’s current share price compares with its recent performance and...

Earlier in January 2026, Alumis Inc. reported positive topline Phase 3 ONWARD1 and ONWARD2 results for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis and subsequently completed a US$300.05 million follow-on common stock offering at US$17.00 per share. A key angle for investors is how envudeucitinib’s differentiated clinical profile and “pipeline-in-a-pill” potential, including possible applications in systemic lupus erythematosus, could influence Alumis’s...

In early January 2026, Caris Life Sciences announced a partnership with digital health company Everlywell to launch Caris Detect, a multi-cancer early detection blood test that applies whole genome sequencing and AI to identify molecular signals of cancer in the bloodstream, with commercialization planned through Everlywell’s platform in the first half of 2026. This collaboration highlights how advanced genomic screening and consumer-focused digital health distribution could broaden access...

Recently, two senior Robert Half executives, Paul F. Gentzkow and George Denlinger, were named to Staffing Industry Analysts’ 2026 North America Staffing 100 list, recognizing their long-term leadership in talent and consulting services. This industry recognition, alongside commentary about resilient consulting operations and easing macroeconomic pressures, highlights how management strength may support Robert Half’s positioning in a gradually improving staffing landscape. We’ll now examine...

Alexandria Real Estate Equities (ARE) is back in focus after investors filed multiple securities class action lawsuits related to its Long Island City property, following weaker than expected 2025 results and a large impairment charge. See our latest analysis for Alexandria Real Estate Equities. The latest legal actions and impairment news come after a volatile stretch where the share price return has recently improved, with a 30 day share price return of 18.41% and year to date share price...

If you are wondering whether Asana's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. At a last close of US$11.42, the stock has seen a 15.7% decline over the past week, a 19.2% decline over the past month, an 11.9% decline year to date, and a 41.9% decline over the past year, with a 71.1% decline over five years and an 18.7% decline over three years. Recent attention on Asana has centered on how its work...

If you are wondering whether Viavi Solutions at around US$17.80 is still good value after a strong run, you are not alone. The stock has pulled back 4.0% over the last week and is slightly lower over the past month and year to date, yet it is still up 75.5% over 1 year and 59.8% over 3 years, with a 5 year return of 9.7%. Recently, news flow around Viavi Solutions has focused on its role as a provider of network testing and monitoring equipment, particularly for telecoms and data center...

If you are wondering whether IMAX at around US$35.07 is still good value after its run, this article will walk through what the current share price might be implying. The stock has had a mixed run recently, with a 2.8% gain over the last week, a 10.2% decline over the last month, and returns of 54.0% over 1 year, 120.6% over 3 years, and 88.3% over 5 years. Recent attention on IMAX has centered on box office trends and its position in premium large format cinema, as investors assess how...

Context for ServiceNow’s recent share performance ServiceNow (NOW) has been under pressure recently, with the stock showing a 2.6% decline over the past day, a 10.8% drop over the past week, and deeper losses over the past month and past 3 months. See our latest analysis for ServiceNow. Zooming out, ServiceNow’s recent share price weakness, including the 1 year total shareholder return of 36.15% in the red and the year to date share price return of 8.71% in the red, points to fading momentum...

Why a Panama LNG lawsuit has put AES (AES) under the spotlight A new civil lawsuit in Virginia, accusing AES (AES) of working with partners to exclude Sinolam from Panama’s LNG to power market and seeking over US$4b in damages, has sharply focused investor attention. See our latest analysis for AES. At a share price of US$14.00, AES has a year to date share price return of a 5.53% decline, while the 1 year total shareholder return of 26.25% contrasts with a 3 year total shareholder return of...

If you are wondering whether Lamar Advertising at around US$130.78 is offering fair value today, you are not alone. This article will walk through what that price really buys you as an investor. The stock has recently posted returns of 2.8% over 7 days, 3.0% over 30 days, 5.4% year to date, 15.5% over 1 year, 50.2% over 3 years and 97.4% over 5 years, so recent performance is front of mind for many holders. Recent headlines around Lamar Advertising have mainly focused on its position in the...

What recent performance says about Watsco (WSO) Without a specific news headline driving attention today, Watsco (WSO) is drawing interest after a mixed run for shareholders, with a 1 day decline, solid recent gains, and a weaker past year overall. See our latest analysis for Watsco. At a share price of $372.51, Watsco has paired a 7 day share price return of 6.6% and a 1 month share price return of 8.1% with a weaker 1 year total shareholder return of 20.2% and stronger multi year gains...

If you are wondering whether QUALCOMM is priced fairly or if the recent pullback has created an opportunity, this article walks through the key numbers so you can judge the current price for yourself. After a 7 day return of an 8.7% decline and a 30 day return of an 8.2% decline, QUALCOMM now sits at a last close of US$164.54, with returns of a 4.9% decline year to date, 2.3% over 1 year, 44.3% over 3 years, and 11.3% over 5 years. Recent headlines around QUALCOMM have focused on its role in...

If you are wondering whether Hologic’s current share price reflects its underlying worth, this article will walk through what the numbers are actually saying about value. The stock last closed at US$75.16, with returns of 0.3% over the past week, around 0.0% over the last month, 0.8% year to date, 9.3% over 1 year, a 4.8% decline over 3 years, and a 2.7% decline over 5 years, which gives you a mixed picture of recent and longer term performance. Recent coverage around Hologic has focused on...

KULR Technology Group (KULR) drew investor attention after securing a five year preferred battery supply agreement with Caban Energy, a deal projected to generate about US$30 million in revenue starting in 2026. See our latest analysis for KULR Technology Group. The Caban agreement lands as momentum in KULR Technology Group's shares has picked up recently, with a 1 month share price return of 21.26% and a year to date share price return of 26.56%. However, the 1 year total shareholder return...

Earlier this month, Butterfly Network, Inc. announced plans to release its Beam Steering API in the first half of 2026, opening previously internal capabilities like iQ Slice™ and iQ Fan™ to external developers within its Butterfly Garden™ and Ultrasound-on-Chip™ programs. This move could broaden third-party AI innovation around Butterfly’s platform and make high-quality portable ultrasound imaging more accessible to clinicians with varying experience levels across multiple care...

In January 2026, AtriCure reported preliminary 2025 results and issued 2026 guidance, projecting approximately US$600 million to US$610 million in revenue and expecting positive adjusted EBITDA, net income, and cash flow, while also highlighting new product launches and completion of enrollment in a key clinical trial. The company simultaneously extended its asset-based revolving credit facility by three years on improved terms, lowering interest costs and adding flexibility that could...